ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

IBUPROFEN; METHOCARBAMOL

Disponibbli minn:

TEVA CANADA LIMITED

Kodiċi ATC:

M03BA53

INN (Isem Internazzjonali):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Dożaġġ:

200MG; 500MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

18/40

Tip ta 'preskrizzjoni:

OTC

Żona terapewtika:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0248961001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2021-08-12

Karatteristiċi tal-prodott

1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................